Nurix Therapeutics Inc (NAS:NRIX)
$ 15.9 0.95 (6.35%) Market Cap: 970.97 Mil Enterprise Value: 698.12 Mil PE Ratio: 0 PB Ratio: 4.35 GF Score: 67/100

Nurix Therapeutics Inc at Piper Sandler Healthcare Conference Transcript

Nov 30, 2022 / 09:30PM GMT
Release Date Price: $12.39 (+5.81%)
Joe Catanzaro
Piper Sandler Companies - Analyst

We'll kick things off here with the last fireside chat session of the day here. But thanks, everybody, for joining us here at Piper Sandler's Annual Healthcare Conference. I'm Joe Catanzaro from the Piper biotech research team. It's my real pleasure to welcome Nurix Therapeutics and their CEO, Arthur Sands. Arthur, thanks so much for making the time here.

Obviously, you guys have a ton going on, and a ton to talk about here in a short 25 minutes. But maybe first, I can give you a sort of brief window here to just give a rundown of Nurix, and what you guys have been up to, and what we have to look forward to.

Arthur Sands
Nurix Therapeutics, Inc. - President, CEO, and Director

Certainly. And thanks, Joe, for having us. So, Nurix, we have four programs in the clinic now in oncology, in leukemia and lymphomas, and also in solid tumors. So, we indeed have a lot of programs to keep updating everyone on, and we appreciate the opportunity.

We create small molecules that modulate protein levels. So,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot